{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:47:53Z","timestamp":1792640873686,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.xphs.2020.12.012","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T04:27:26Z","timestamp":1608179246000},"page":"2121-2129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Physicochemical Characterization of Sabin Inactivated Poliovirus Vaccine for Process Development"],"prefix":"10.1016","volume":"110","author":[{"given":"Tetsuo","family":"Torisu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Shikama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Maruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Satou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.xphs.2020.12.012_bib1","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1021\/ac400968q","article-title":"Isoelectric point determination of live polioviruses by capillary isoelectric focusing with whole column imaging detection","volume":"85","author":"Thomassen","year":"2013","journal-title":"Anal Chem"},{"key":"10.1016\/j.xphs.2020.12.012_bib2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41579-018-0005-4","article-title":"The life cycle of non-polio enteroviruses and how to target it","volume":"16","author":"Baggen","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.xphs.2020.12.012_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.molimm.2014.07.014","article-title":"Structural studies of virus-antibody immune complexes (poliovirus type I): characterization of the epitopes in 3D","volume":"63","author":"Bannwarth","year":"2015","journal-title":"Mol Immunol"},{"issue":"18","key":"10.1016\/j.xphs.2020.12.012_bib4","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.xphs.2020.12.012_bib5","first-page":"1","article-title":"On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine","volume":"6736","author":"Peng","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2020.12.012_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.biologicals.2018.03.002","article-title":"Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures","volume":"53","author":"White","year":"2018","journal-title":"Biologicals"},{"issue":"35","key":"10.1016\/j.xphs.2020.12.012_bib7","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/j.vaccine.2015.03.076","article-title":"sIPV process development for costs reduction","volume":"33","author":"Thomassen","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.xphs.2020.12.012_bib8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.biologicals.2016.07.004","article-title":"Introduction to the application of QbD principles for the development of monoclonal antibodies","volume":"44","author":"Finkler","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.xphs.2020.12.012_bib9","doi-asserted-by":"crossref","first-page":"12504","DOI":"10.1021\/bi00207a018","article-title":"Classification of acid denaturation of proteins: intermediates and unfolded states","volume":"33","author":"Fink","year":"1944","journal-title":"Biochemistry"},{"key":"10.1016\/j.xphs.2020.12.012_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ab.2015.07.013","article-title":"Denatured state aggregation parameters derived from concentration dependence of protein stability","volume":"488","author":"Sch\u00f6n","year":"2015","journal-title":"Anal Biochem"},{"issue":"4","key":"10.1016\/j.xphs.2020.12.012_bib11","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/prot.21243","article-title":"Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies","volume":"66","author":"Ejima","year":"2007","journal-title":"Proteins Struct Funct Genet"},{"issue":"1","key":"10.1016\/j.xphs.2020.12.012_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/jps.23801","article-title":"Preformulation study of highly purified inactivated polio vaccine, serotype 3","volume":"103","author":"Qi","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2020.12.012_bib13","doi-asserted-by":"crossref","first-page":"E590","DOI":"10.1208\/aapsj080368","article-title":"Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals","volume":"8","author":"Berkowitz","year":"2006","journal-title":"AAPS J"},{"issue":"1-2","key":"10.1016\/j.xphs.2020.12.012_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jviromet.2007.04.008","article-title":"Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: correlation of particle counts, size distribution and infectivity","volume":"144","author":"Wei","year":"2007","journal-title":"J\u00a0Virol Methods"},{"key":"10.1016\/j.xphs.2020.12.012_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jviromet.2017.06.002","article-title":"Biophysical characterization of influenza A virions","volume":"247","author":"Parupudi","year":"2017","journal-title":"J\u00a0Virol Methods"},{"issue":"3","key":"10.1016\/j.xphs.2020.12.012_bib16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/jps.23001","article-title":"Particles in therapeutic protein formulations, Part 1: overview of analytical methods","volume":"101","author":"Z\u00f6lls","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2020.12.012_bib17","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1016\/j.xphs.2017.07.024","article-title":"Recent topics of research in the characterization and quality control of biopharmaceuticals in Japan","volume":"106","author":"Ishii-Watabe","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2020.12.012_bib18","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1002\/jps.22097","article-title":"An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics","volume":"99","author":"Singh","year":"2010","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.12.012_bib19","doi-asserted-by":"crossref","unstructured":"Charney J, Machlowitz R, Tytell AA, Sagin JF, Spicer DS. The Concentration and Purification of Poliomyelitis Virus by the Use of Nucleic Acid Precipitation. Vol 16.;\u00a01961.","DOI":"10.1016\/0042-6822(61)90358-0"},{"key":"10.1016\/j.xphs.2020.12.012_bib20","series-title":"The Molecular Biology of Polio Virus","author":"Koch","year":"1985"},{"key":"10.1016\/j.xphs.2020.12.012_bib21","series-title":"Poliovirus-Methods and Protocols","first-page":"299","article-title":"Measuring poliovirus antigenicity by surface plasmon resonance. Application for potency indicating assays","author":"Westdijk","year":"2016"},{"issue":"18","key":"10.1016\/j.xphs.2020.12.012_bib22","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.xphs.2020.12.012_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ab.2006.11.031","article-title":"Monitoring the homogeneity of adenovirus preparations (a gene therapy delivery system) using analytical ultracentrifugation","volume":"362","author":"Berkowitz","year":"2007","journal-title":"Anal Biochem"},{"issue":"26","key":"10.1016\/j.xphs.2020.12.012_bib24","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1021\/bi020099h","article-title":"Determination of active concentrations and association and dissociation rate constants of interacting biomolecules: an analytical solution to the theory for kinetic and mass transport limitations in biosensor technology and its experimental verification","volume":"41","author":"Sigmundsson","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.xphs.2020.12.012_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejpb.2018.05.021","article-title":"The effect of formulation on spray dried Sabin inactivated polio vaccine","volume":"129","author":"Kanojia","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"issue":"27","key":"10.1016\/j.xphs.2020.12.012_bib26","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1016\/j.vaccine.2016.04.046","article-title":"Asymmetrical flow field-flow fractionation coupled with multi-angle laser light scattering for stability comparison of virus-like particles in different solution environments","volume":"34","author":"Chen","year":"2016","journal-title":"Vaccine"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920307917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920307917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:34:05Z","timestamp":1758360845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920307917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0022354920307917"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.12.012","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physicochemical Characterization of Sabin Inactivated Poliovirus Vaccine for Process Development","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}